<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC3764029/results/search/drug/results.xml">
  <result pre="pmid: 24040153PONE-D-13-16036 doi: 10.1371/journal.pone.0074027 : Research Article Sensitivity of a" exact="Ribavirin" post="Resistant Mutant of Hepatitis C Virus to Other Antiviral"/>
  <result pre="C Virus to Other Antiviral Drugs HCV Cross Resistance to" exact="Ribavirin" post="and Other Drugs MihalikKathleen B.FeigelstockDino A.*[], Division of Viral"/>
  <result pre="used by anyone for any lawful purpose. Abstract Background While" exact="ribavirin" post="mono-therapy regimens have minimal effect on patients with chronic"/>
  <result pre="with interferon. Clinical studies show that interferon-free combination therapies containing" exact="ribavirin" post="are also efficacious, suggesting that an interferon-free therapy could"/>
  <result pre="the treatment. Therefore, understanding the mechanism of HCV resistance to" exact="ribavirin" post="and cross resistance to other antiviral drugs could be"/>
  <result pre="Methods We tested the ability of a J6/JFH1 derived HCV" exact="ribavirin" post="resistant mutant to grow in tissue cultured Huh7D cells"/>
  <result pre="tissue cultured Huh7D cells in the presence of the mutagen" exact="5-Fluorouracil" post="and the nucleoside analog 2′-C-Methylcytidine. Virus replication was assessed"/>
  <result pre="tested drugs varied. HCV-RR was more resistant than J6/JFH1 to" exact="5-Fluorouracil" post="but was not more resistant than J6/JFH1 to 2′-C-Methylcytidine."/>
  <result pre="more resistant than J6/JFH1 to 2′-C-Methylcytidine. Growth of HCV-RR in" exact="5-Fluorouracil" post="allowed the selection of an HCV-RR derived mutant resistant"/>
  <result pre="allowed the selection of an HCV-RR derived mutant resistant to" exact="5-Fluorouracil" post="(HCV-5FU). HCV-5FU grows to moderate levels in the presence"/>
  <result pre="to moderate levels in the presence of high concentrations of" exact="5-Fluorouracil" post="and to parental levels in the absence of the"/>
  <result pre="mutations. Conclusions These results indicate that determinants of resistance to" exact="ribavirin" post="could also confer resistance to other anti-HCV drugs, shedding"/>
  <result pre="drugs, shedding light toward understanding the mechanism of action of" exact="ribavirin" post="and highlighting the importance of combination drug selection for"/>
  <result pre="results also show that it is possible to select a" exact="5-Fluorouracil" post="HCV resistant mutant that replicates to levels similar to"/>
  <result pre="HCV infected patients consists of a combination of pegylated interferon" exact="alpha" post="and ribavirin [4]. Recently, two protease inhibitors were approved"/>
  <result pre="patients consists of a combination of pegylated interferon alpha and" exact="ribavirin" post="[4]. Recently, two protease inhibitors were approved by the"/>
  <result pre="HCV infections is highly desirable. Recent studies have shown that" exact="ribavirin" post="in combination with other antiviral drugs, without interferon, can"/>
  <result pre="be efficacious [7], [8], suggesting that an interferon-free therapy containing" exact="ribavirin" post="could be adopted in the near future. However, generation"/>
  <result pre="treatment. In addition, the anti HCV mechanism of action of" exact="ribavirin" post="is not completely elucidated. Several mechanisms of action of"/>
  <result pre="ribavirin is not completely elucidated. Several mechanisms of action of" exact="ribavirin" post="against HCV were proposed including a direct effect against"/>
  <result pre="[10]. In order to study the cross-resistance of HCV to" exact="ribavirin" post="and other antiviral drugs that could have a mechanism"/>
  <result pre="we tested the ability of a J6/JFH1 [11] HCV derived" exact="ribavirin" post="resistant mutant, HCV-RR [12], to grow in the presence"/>
  <result pre="[12], to grow in the presence of the pyrimidine analog" exact="5-Fluorouracil" post="and the nucleoside analog 2′-C-Methylcytidine in Huh7D cells (a"/>
  <result pre="(a Huh7 cell derivative more permissive to HCV replication) [13]." exact="5-Fluorouracil" post="is broadly used in the clinic to treat cancer"/>
  <result pre="to treat cancer [14] including HCV associated hepatocellular carcinoma [15]." exact="5-Fluorouracil" post="displays mutagenic activity leading to viral extinction in different"/>
  <result pre="a similar lethal mutagenic effect has also been observed for" exact="ribavirin" post="on several viruses including poliovirus [17], coxsackievirus B3 [18],"/>
  <result pre="[21], and Hantaan virus [22]. It has been shown that" exact="ribavirin" post="also has a mutagenic effect on HCV, increasing its"/>
  <result pre="in vivo [25], [27]. Deep sequencing has recently revealed that" exact="ribavirin" post="exerts mutagenic activity in chronic HCV infected patients by"/>
  <result pre="cell-free biochemical assays [36]. It has also been shown that" exact="ribavirin" post="antagonizes the in vitro anti-HCV activity of 2′-C-Methylcytidine [37],"/>
  <result pre="this study we show that an HCV mutant resistant to" exact="ribavirin" post="is more resistant than parental J6/JFH1 to 5-Fluorouracil, but"/>
  <result pre="resistant than parental J6/JFH1 to 2′-C-Methylcytidine. These results indicate that" exact="ribavirin" post="resistant viruses could have elevated resistance to other inhibitors,"/>
  <result pre="light toward the understanding of the mechanism of action of" exact="ribavirin" post="and HCV resistance to this drug. In addition, the"/>
  <result pre="to this drug. In addition, the growth of HCV-RR in" exact="5-Fluorouracil" post="allowed us to select an HCV mutant resistant to"/>
  <result pre="5-Fluorouracil allowed us to select an HCV mutant resistant to" exact="5-Fluorouracil" post="that can replicate in vitro to moderate levels in"/>
  <result pre="the presence of concentrations as high as 3 µ/ml of" exact="5-Fluorouracil" post="and to parental levels in the absence of drug."/>
  <result pre="and to parental levels in the absence of drug. The" exact="5-Fluorouracil" post="resistant virus accumulated multiple mutations distributed throughout the HCV"/>
  <result pre="HCV genome. Results Growth of HCV in the Presence of" exact="5-Fluorouracil" post="In order to test the sensitivity of an HCV"/>
  <result pre="5-Fluorouracil In order to test the sensitivity of an HCV" exact="ribavirin" post="resistant mutant to 5-Fluorouracil, parental J6/JFH1 [11] and J6/JFH1"/>
  <result pre="grown in zero, 0.5, 1, 2, and 5 µg/ml of" exact="5-Fluorouracil" post="by serially passaging the viruses every 7 days in"/>
  <result pre="obtained. The result indicates that HCV-RR2 is more resistant to" exact="5-Fluorouracil" post="than parental J6/JFH1. Figure 1 Growth of HCV in"/>
  <result pre="of 2′-C-Methylcytidine In order to test sensitivity of an HCV" exact="ribavirin" post="resistant mutant to 2′-C-Methylcytidine, parental J6/JFH1 and HCV-RR2 were"/>
  <result pre="result confirms the differential sensitivity of J6/JFH1 and HCV-RR2 to" exact="5-Fluorouracil" post="and 2′-C-Methylcytidine. We note variations in the growth of"/>
  <result pre="and HCV-RR2 grew to a lesser extent in 2 µg/ml" exact="5-Fluorouracil" post="in the experiment shown in Figure 3 (see below)"/>
  <result pre="the nature of these variations. Figure 3 HCV recovered from" exact="5-Fluorouracil" post="treated cells is resistant to 5-Fluorouracil. J6/JFH1, HCV-RR2, HCV-5FU-1-P6,"/>
  <result pre="replicates. Error bars represent the standard deviation. Virus Recovered from" exact="5-Fluorouracil" post="Treated Cells is Resistant to 5-Fluorouracil The enhanced growth"/>
  <result pre="deviation. Virus Recovered from 5-Fluorouracil Treated Cells is Resistant to" exact="5-Fluorouracil" post="The enhanced growth of HCV-RR2 in 5-Fluorouracil (Figure 1)"/>
  <result pre="is Resistant to 5-Fluorouracil The enhanced growth of HCV-RR2 in" exact="5-Fluorouracil" post="(Figure 1) prompted us to obtain a 5-Fluorouracil HCV"/>
  <result pre="HCV-RR2 in 5-Fluorouracil (Figure 1) prompted us to obtain a" exact="5-Fluorouracil" post="HCV resistant virus. To that end, we subjected HCV-RR2"/>
  <result pre="days each in Huh7D cells treated with 2.5 µg/ml of" exact="5-Fluorouracil" post="followed by a) one passage of 7 days in"/>
  <result pre="a) one passage of 7 days in medium containing no" exact="5-Fluorouracil" post="to obtain HCV-5FU-1 or b) two passages (of 3"/>
  <result pre="passages (of 3 and 7 days) in medium containing no" exact="5-Fluorouracil" post="to obtain HCV-5FU-2. These last passages in medium containing"/>
  <result pre="HCV-5FU-2 were grown in 0, 1.5, 2 and 2.5 µg/ml" exact="5-Fluorouracil" post="by serially passaging the viruses every 7 days in"/>
  <result pre="2.5 µg/ml 5-Fluorouracil. This result indicates that viruses recovered from" exact="5-Fluorouracil" post="treated cells were more resistant to 5-Fluorouracil than parental"/>
  <result pre="viruses recovered from 5-Fluorouracil treated cells were more resistant to" exact="5-Fluorouracil" post="than parental HCV-RR2. HCV-5FU-1 and HCV-5FU-2 that were passed"/>
  <result pre="and HCV-5FU-2 that were passed six times in 2.5 µg/ml" exact="5-Fluorouracil" post="in the experiment shown in Figure 3 (designated HCV-5FU-1-P6"/>
  <result pre="tested for their resistance to 2.5 µg/ml and 3 µg/ml" exact="5-Fluorouracil" post="in Huh7D cells. All viruses grew in the absence"/>
  <result pre="HCV-5FU-1 and HCV-5FU-2, HCV-5FU-1-P6 and HCV-5FU-2-P6 grew in 2.5 µg/ml" exact="5-Fluorouracil" post="achieving titers higher than 103 ffu/ml, while J6/JFH1 and"/>
  <result pre="not grow. Furthermore, HCV-5FU-1-P6 and HCV-5FU-2-P6 grew in 3 µg/ml" exact="5-Fluorouracil" post="achieving titers higher than 102 and 103 ffu/ml respectively,"/>
  <result pre="of the drug (Figure 4) and are still resistant to" exact="ribavirin" post="(not shown). Figure 4 Further passage of HCV in"/>
  <result pre="ribavirin (not shown). Figure 4 Further passage of HCV in" exact="5-Fluorouracil" post="yields viruses resistant to 3 µg/ml concentration of 5-Fluorouracil."/>
  <result pre="deviation. Kinetics of Virus Growth in 2 and 3 µM" exact="5-Fluorouracil" post="for One Week We studied the 5-Fluorouracil resistant phenotype"/>
  <result pre="and 3 µM 5-Fluorouracil for One Week We studied the" exact="5-Fluorouracil" post="resistant phenotype of HCV-5FU-1-P6 and HCV-5FU-2-P6 by determining the"/>
  <result pre="in a concentration of 0, 2, and 3 µg/ml of" exact="5-Fluorouracil" post="for one week as described in the material and"/>
  <result pre="in medium containing concentrations of 2 and 3 µg/ml of" exact="5-Fluorouracil" post="(Figure 5). Interestingly, HCV-5FU-1-P6 and HCV-5FU-2-P6 grew to slightly"/>
  <result pre="HCV-5FU-2-P6 grew to slightly higher titers in medium containing no" exact="5-Fluorouracil" post="when compared to J6/JFH1 and parental HCV-RR2 (see Figures"/>
  <result pre="Growth of HCV in 2 and 3 µg/ml concentration of" exact="5-Fluorouracil" post="for one week. Huh7D cells were mock infected or"/>
  <result pre="replicates. Error bars represent the standard deviation. Virus Resistant to" exact="5-Fluorouracil" post="′and Non-synonymous Mutations In order to find out if"/>
  <result pre="5-Fluorouracil ′and Non-synonymous Mutations In order to find out if" exact="5-Fluorouracil" post="resistant viruses acquired mutations, viral RNA from HCV-5FU-1-P6 and"/>
  <result pre="deduced amino acid changes in early passages of HCV-RR2 in" exact="5-Fluorouracil" post="at positions found mutated in HCV-5FU-1-P6. Nucleotide* HCV-RR2 P1"/>
  <result pre="In this study we compared the growth of an HCV" exact="ribavirin" post="resistant mutant (HCV-RR2) to the growth of its parental"/>
  <result pre="in the presence of two antiviral drugs: the mutagenic pyrimidine" exact="5-Fluorouracil" post="and the nucleoside analog 2′-C-Methylcytidine. We show that HCV"/>
  <result pre="the nucleoside analog 2′-C-Methylcytidine. We show that HCV resistant to" exact="ribavirin" post="is more resistant to 5-Fluorouracil but is not more"/>
  <result pre="show that HCV resistant to ribavirin is more resistant to" exact="5-Fluorouracil" post="but is not more resistant to 2′-C-Methylcytidine (Figures 1"/>
  <result pre="2) than it parental virus J6/JFH1. By passaging HCV-RR2 in" exact="5-Fluorouracil" post="we selected HCV-RR2 resistant to 5-Fluorouracil (HCV-5FU). We confirmed"/>
  <result pre="By passaging HCV-RR2 in 5-Fluorouracil we selected HCV-RR2 resistant to" exact="5-Fluorouracil" post="(HCV-5FU). We confirmed the 5-Fluorouracil resistant phenotype of HCV-5FU"/>
  <result pre="we selected HCV-RR2 resistant to 5-Fluorouracil (HCV-5FU). We confirmed the" exact="5-Fluorouracil" post="resistant phenotype of HCV-5FU viruses by infecting naïve cells"/>
  <result pre="they can grow even in a concentration of 3 µg/ml" exact="5-Fluorouracil" post="(Figures 3, 4, and 5). HCV-5FU resistant to 5-Fluorouracil"/>
  <result pre="µg/ml 5-Fluorouracil (Figures 3, 4, and 5). HCV-5FU resistant to" exact="5-Fluorouracil" post="acquired synonymous and non-synonymous mutations that were distributed all"/>
  <result pre="along the genome (Table 1). The mechanism of action of" exact="ribavirin" post="against HCV in vitro and in vivo and the"/>
  <result pre="vitro and in vivo and the mechanism of resistance to" exact="ribavirin" post="by HCV ribavirin resistant mutants has not been completely"/>
  <result pre="vivo and the mechanism of resistance to ribavirin by HCV" exact="ribavirin" post="resistant mutants has not been completely elucidated. The differential"/>
  <result pre="been completely elucidated. The differential sensitivity observed for HCV-RR2 to" exact="5-Fluorouracil" post="and 2′-C-Methylcytidine when compared to parental J6/JFH1 virus indicates"/>
  <result pre="activity of ribavirin. This is supported by the fact that" exact="5-Fluorouracil" post="is a pyrimidine analog and 2′-C-Methylcytidine and ribavirin are"/>
  <result pre="fact that 5-Fluorouracil is a pyrimidine analog and 2′-C-Methylcytidine and" exact="ribavirin" post="are both nucleoside analogs. Given the nature of these"/>
  <result pre="nature of these drugs, it is tempting to speculate that" exact="ribavirin" post="acts on HCV at the RNA replication level, as"/>
  <result pre="shown for 2′-C-Methylcytidine [36]. We previously showed that an HCV" exact="ribavirin" post="resistant mutant has mutations in different positions of its"/>
  <result pre="that the RNA dependent RNA polymerase from HCV can use" exact="ribavirin" post="triphosphate as a nucleotide substrate. Once ribavirin monophosphate has"/>
  <result pre="HCV can use ribavirin triphosphate as a nucleotide substrate. Once" exact="ribavirin" post="monophosphate has been incorporated in the nascent chain, it"/>
  <result pre="RNA elongation [38], [39]. As noted above, mutagenic activity of" exact="ribavirin" post="on HCV has been observed in vivo and in"/>
  <result pre="We found that HCV-RR2 was more resistant to the mutagen" exact="5-Fluorouracil" post="than its parental J6/JFH1. This indicates that determinants conferring"/>
  <result pre="its parental J6/JFH1. This indicates that determinants conferring resistance to" exact="ribavirin" post="also confer resistance to 5-Fluorouracil and could confer resistance"/>
  <result pre="that determinants conferring resistance to ribavirin also confer resistance to" exact="5-Fluorouracil" post="and could confer resistance to other antiviral drugs. Cross"/>
  <result pre="drug treatments. Given the observed efficacy of the inclusion of" exact="ribavirin" post="in interferon free regimens in the treatment of chronic"/>
  <result pre="the treatment of chronic HCV, cross resistance of HCV to" exact="ribavirin" post="and to other antiviral drugs could be of major"/>
  <result pre="In FMDV, a single point mutation (M296I) confers resistance to" exact="ribavirin" post="[40]. This mutant was as sensitive as wild type"/>
  <result pre="wild type FMDV to 5-fluorouracil when administered in combination with" exact="guanidine" post="hydrochloride, indicating that mutation M296I did not confer a"/>
  <result pre="the action of antiviral drugs. Of note, the concentrations of" exact="ribavirin" post="(5 mM) and 5-Fluorouracil (200 or 500 µg/ml) for"/>
  <result pre="drugs. Of note, the concentrations of ribavirin (5 mM) and" exact="5-Fluorouracil" post="(200 or 500 µg/ml) for the treatment of BHK-21"/>
  <result pre="in our study. We isolated an HCV mutant resistant to" exact="5-Fluorouracil" post="(HCV-5FU). To our knowledge, no 5-Fluorouracil resistant viruses, including"/>
  <result pre="HCV mutant resistant to 5-Fluorouracil (HCV-5FU). To our knowledge, no" exact="5-Fluorouracil" post="resistant viruses, including HCV, have been previously reported. When"/>
  <result pre="(Table 1). Mutation A8483G encodes a change from threonine to" exact="alanine" post="at amino-acid 273 of NS5b, which, according to its"/>
  <result pre="[12]. Mutations in the finger domain have been identified in" exact="ribavirin" post="resistant mutants of poliovirus [44], [45]. Five other non-synonymous"/>
  <result pre="viral replication. Conclusion In this report, we show that a" exact="ribavirin" post="resistant mutant of HCV has differential sensitivity to other"/>
  <result pre="suggests that mutations that are responsible for HCV resistance to" exact="ribavirin" post="can be involved in the sensitivity to other drugs,"/>
  <result pre="clinically important for drug selection, since an interferon-free regimen containing" exact="ribavirin" post="for the treatment of HCV infections seems currently plausible."/>
  <result pre="to the potent mutagen 5-Fluorouracil. This mutant when grown without" exact="5-Fluorouracil" post="can replicate to parental levels. Analysis of the mutations"/>
  <result pre="to parental levels. Analysis of the mutations responsible for the" exact="5-Fluorouracil" post="resistance phenotype may aid in understanding the mechanism of"/>
  <result pre="phenotype may aid in understanding the mechanism of action of" exact="5-Fluorouracil" post="and other antivirals against HCV. Methods Cells Huh7D cells,"/>
  <result pre="10% bovine calf serum (Atlanta Biologicals), L-glutamine (Gibco), penicillin, and" exact="streptomycin" post="(Gibco). Viruses Virus J6/JFH1 was obtained from plasmid pFL-"/>
  <result pre="Cells with J6/JFH1, HCV-RR, and HCV-5FU Viruses and Treatment with" exact="5-Fluorouracil" post="or 2′-C-Methylcytidine Huh7D cells grown in 48-well plates were"/>
  <result pre="with 500 µl of medium containing the indicated amount of" exact="5-Fluorouracil" post="(Sigma) or 2′-C-Methylcytidine (USBiological). At 7 days post infection,"/>
  <result pre="from the supernatants as described below. Growth of HCV in" exact="5-Fluorouracil" post="or 2′-C-Methylcytidine for One Week Huh7D cells grown in"/>
  <result pre="a final concentration of zero, 2, or 3 µg/ml of" exact="5-Fluorouracil" post="or 0.625, 1.25, 2.5, 5, or 10 µM concentration"/>
  <result pre="−70°C. Wells were supplemented with medium containing corresponding concentration of" exact="5-Fluorouracil" post="or 2′-C-Methylcytidine. Virus from each time point was titered"/>
  <result pre="over the total number of cells per well. Sequencing of" exact="Ribavirin" post="Resistant Viruses Viral RNA was extracted from virus stocks"/>
  <result pre="ShiffmanML, ReddyKR, SmithC, MarinosG, et al. (2002) Peginterferon alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C virus infection. N Engl J"/>
  <result pre="975–982doi:;10.1056/NEJMoa020047;347/13/97512324553 5ShermanKE, FlammSL, AfdhalNH, NelsonDR, SulkowskiMS, et al. (2011) Response-guided" exact="telaprevir" post="combination treatment for hepatitis C virus infection. N Engl"/>
  <result pre="polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus" exact="ribavirin" post="in hepatitis C. Hepatology. 55: 749–758doi:10.1002/hep.24744 8ZeuzemS, AsselahT, AngusP,"/>
  <result pre="the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and" exact="ribavirin" post="in patients with chronic HCV infection. Gastroenterology 1412047–2055: S0016–5085(11)01248-0doi:10.1053/j.gastro.2011.08.051"/>
  <result pre="LiangTJ, et al. (2008) Mechanisms of action of interferon and" exact="ribavirin" post="in chronic hepatitis C: Summary of a workshop. Hepatology47:"/>
  <result pre="Hepatology47: 306–320.18161743 10FeldJJ, LutchmanGA, HellerT, HaraK, PfeifferJK, et al. (2010)" exact="Ribavirin" post="improves early responses to peginterferon through improved interferon signaling."/>
  <result pre="ArnoldJJ, ZhongW, LauJY, et al. (2000) The broad-spectrum antiviral ribonucleoside" exact="ribavirin" post="is an RNA virus mutagen. Nat Med6: 1375–1379.11100123 18GraciJD,"/>
  <result pre="Curing of foot-and-mouth disease virus from persistently infected cells by" exact="ribavirin" post="involves enhanced mutagenesis. Virology 311339–349: S0042682203001442. 20Day CW, Smee"/>
  <result pre="S0166–3542(05)00077-X; doi:10.1016/j.antiviral.2005.04.002. 21LanfordRE, ChavezD, GuerraB, LauJY, HongZ, et al. (2001)" exact="Ribavirin" post="induces error-prone replication of GB virus B in primary"/>
  <result pre="tamarin hepatocytes. J Virol75: 8074–8081.11483752 22SeversonWE, SchmaljohnCS, JavadianA, JonssonCB (2003)" exact="Ribavirin" post="causes error catastrophe during Hantaan virus replication. J Virol77:"/>
  <result pre="23BrochotE, DuverlieG, CastelainS, MorelV, WychowskiC, et al. (2007) Effect of" exact="ribavirin" post="on the hepatitis C virus (JFH-1) and its correlation"/>
  <result pre="(2002) Viral RNA mutations are region specific and increased by" exact="ribavirin" post="in a full-length hepatitis C virus replication system. J"/>
  <result pre="PoltaA, HerrmannE, MihmU, KronenbergerB, et al. (2007) Mutagenic effect of" exact="ribavirin" post="on hepatitis C nonstructural 5B quasispecies in vitro and"/>
  <result pre="Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells:" exact="ribavirin" post="induces mutagenesis in HCV RNA. J Viral Hepat11: 479–487.15500548"/>
  <result pre="the hepatitis C virus NS5B in patients undergoing treatment with" exact="ribavirin" post="monotherapy. Gastroenterology132: 1757–1766.17484873 28DietzJ, SchelhornSE, FittingD, MihmU, SusserS, et"/>
  <result pre="SusserS, et al. (2013) Deep sequencing reveals mutagenic effects of" exact="ribavirin" post="during monotherapy of hepatitis C virus genotype 1-infected patients."/>
  <result pre="Virology351: 349–359.16713611 37CoelmontL, PaeshuyseJ, WindischMP, DeCE, BartenschlagerR, et al. (2006)" exact="Ribavirin" post="antagonizes the in vitro anti-hepatitis C virus activity of"/>
  <result pre="46094–46098.11602568 39VoNV, YoungKC, LaiMM (2003) Mutagenic and inhibitory effects of" exact="ribavirin" post="on hepatitis C virus RNA polymerase. Biochemistry42: 10462–10471.12950173 40SierraM,"/>
 </snippets>
</snippetsTree>
